Last updated: August 17, 2026
6. Crohn’s Disease
Intravenous infusion of autologous MSCs has demonstrated significant efficacy in managing Crohn’s disease by reducing abdominal pain, improving bowel function, and reducing inflammation. MSCs modulate immune responses by suppressing pro-inflammatory cytokines, enhancing regulatory T-cell activity, and promoting mucosal healing. The paracrine signaling of MSCs stimulates epithelial regeneration and reduces the inflammatory response in the gut. These cells migrate to the inflamed intestinal tissues, offering long-lasting improvements in disease control and quality of life.
7. Ulcerative Colitis
MSC therapy provides relief for patients with ulcerative colitis by improving bowel habits, reducing rectal bleeding, and decreasing overall intestinal inflammation. The mechanisms behind MSC effectiveness include immune system modulation by decreasing Th1/Th17 cytokine production, enhancing the regenerative capacity of the intestinal epithelium, and promoting tissue repair. MSCs home to inflamed colon areas via circulating inflammatory signals, effectively reducing chronic inflammation and promoting mucosal healing.
Scientific Case Review
Would you like to understand whether current clinical programs, recent research developments, or emerging approaches may be relevant to your individual situation?
Share your question with our scientific research team and receive information focused on the areas of current research that may be relevant to your case.
- Review of the information you provide
- Relevant research and clinical program information
- A clear response focused on your situation
No obligation. Your question will be reviewed confidentially.
Educational and research information only. This service does not constitute medical advice, diagnosis, prescription, or a personalized treatment recommendation.
